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applied to Kt/Vurea may be applied to Kt/V of other uremic
retention solutes. In conclusion, it is time to work out a new
theory of the adequacy of dialysis: the paper by Eloot et al.1
has the merit of providing experimental data which allow to
separate the effect of t from that of other variables.
Furthermore, it has the merit of simplifying the conceptual
scenario of adequacy of dialysis and of drawing the focus on
the diffusive mechanisms as the key modality of the removal
of uremic retention solutes.1
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To the Editor: We read with interest the article by Lopez
et al.1 They compared the effects of AMG 641 with calcitriol
(CT) or paricalcitol (PC) alone, and the combination of the
calcimimetic with either CT or PC. We have really found the
paper interesting, but would like to raise some points of
discussion.
Not surprisingly, CT administration induced extraskeletal
calcifications (EC), reduced survival, increased aortic calcium
(Ca) and phosphorous deposition, and enhanced mineral
content in the lung and stomach. Contrary to our
expectations and recent literature data, also PC administra-
tion did not prevent EC and aortic Ca and phosphorous
deposition. Unfortunately, the authors did not comment in
their paper to at least other two new published articles with
opposite results on this topic,2,3 and we believe that the
debate needs to be opened.
It is diffusely agreed that dialysis patients develop
extensive EC, which causes increased arterial stiffness and
high morbidity and mortality because of cardiovascular
events. A variety of risk factors are associated with EC in
dialysis patients (time on dialysis, uremic toxins, history of
diabetes, inflammation), but abnormalities in bone mineral
metabolism may play a critical role.4 In this direction, both
vitamin D receptor activators and calcimimetics represent
new tools in the treatment of secondary hyperparathyroidism
and EC.
In experimental animal models, the limited hypercalcemic
effect of PC results from a lower affinity for vitamin D
receptor in intestine and bone. In addition, PC causes a
selective vitamin D activation and a reduction in intestinal
Ca absorption.5 Recently, an in vitro study demonstrated that
CT increased calcification of vascular smooth muscle cells
cultured in calcification media, but this effect was not present
when cells were incubated with PC.2 Moreover, in an in vivo
study Mizobuchi et al.3 showed that both CT and
doxercalciferol significantly increased the serum Ca and
phosphorous product and aortic Ca content in uremic rats.
In contrast, PC had no effect on EC.
Finally, recent prospective studies demonstrated that
hemodialysis patients receiving low doses of PC intrave-
nously have a reduced mortality risk compared to untreated
patients6 and that PC has a survival benefit over CT.7
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We thank Dr Cozzolino and Dr Brancaccio for their interest
in our recently published article in which we investigated the
effect of calcitriol, paricalcitol, and the research calcimimetic
AMG 641, alone or in combination, on the development of
vascular and other soft tissue calcifications in a rat model of
uremia-associated secondary hyperparathyroidism (HPT).
After completing this study we concluded that the calcimi-
metic AMG 641 reduces parathyroid hormone (PTH)
without inducing extraskeletal calcifications under condi-
tions in which the vitamin D derivatives did.1
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Dr Cozzolino and Dr Brancaccio raise the point that,
contrary to their expectations, we reported extraosseous
calcifications in uremic rats treated with paricalcitol. This is
a valid concern which we would like to address and, at the
same time, discuss two more articles on this subject which
were published almost simultaneously to our paper.2,3
Cardus et al.2 have studied, both in vitro and in vivo, the
differential effects of calcitriol and paricalcitol on vascular
calcifications. Contrary to the assertion of Dr Cozzolino
and Dr Brancaccio, the in vivo results reported by Cardus
et al. are quite similar to the results reported in our paper.
The aortic image with calcified foci after treatment with
paricalcitol presented by Cardus et al. is almost identical to
the aortic image reported in our paper. Moreover, Cardus
et al. reported an increase in aortic calcium content in rats
treated with paricalcitol, which in fact is higher than what
we found.
In their paper, Mizobuchi et al.3 showed that neither
aortic calcium content nor von Kossa staining increased in
uremic rats after treatment with paricalcitol. These authors
induced uremia with the same model reported in our paper
(5/6 nephrectomized rats on a high phosphorus diet).
However, a careful reading of their study reveals several
interesting differences: (1) the rats treated with paricalcitol
by Mizobuchi et al. were less uremic (creatinine: 1.1±0.1 mg
per 100 ml) than the rats in our study (creatinine:
1.8±0.9 mg per 100 ml); (2) the rats in the study of
Mizobuchi et al. also had less severe hyperparathyroidism
(PTH: 72±15 vs 191±42 pg/ml in our study); and (3) in the
rats in which they report the biochemical values referenced
above, Mizobuchi et al. administered a lower dose of
paricalcitol, 0.16 vs 0.24 lg/kg in our study. In conclusion,
these rats were less uremic, had a lesser degree of HPT and,
consequently, required a lower dose of paricalcitol to control
secondary HPT than in our study. Mizobuchi et al. also
studied a higher dose of paricalcitol (0.24 lg/kg) but they do
not provide creatinine or PTH values of these rats and thus
it is difficult to compare their results.
Dr Cozzolino and Dr Brancaccio suggest that paricalcitol
exerts a lower affinity for the vitamin D receptor in bone.
However, it is our belief that the literature suggests that
paricalcitol is instead a less potent molecule than calcitriol,
highlighted by the differences in dosing suggested in the
prescribing information. In addition, they mention studies
suggesting that paricalcitol provides a survival benefit in
dialysis patients with respect to untreated patients4 and to
those treated with calcitriol.5 We would like to point out that
these are observational studies, with all of the limitations
inherent in this type of study design, whose conclusions are
not supported by all reports,6 including a recently published
meta analysis by Palmer et al.7
We believe that there is accumulating evidence showing
that paricalcitol induces less vascular calcification than
other vitamin D analogs. In fact, under certain conditions,
paricalcitol may be able to control secondary hyperpar-
athyroidism without inducing calcifications, as shown by
Mizobuchi et al. However, when uremia is severe the doses
of paricalcitol needed to control secondary HPT result in
extraskeletal calcifications whereas calcimimetics are able
to control secondary HPT without inducing calcifications.
Finally, an important point is that these two treatments are
not exclusive since, as reported in our paper, when used in
combination with paricalcitol AMG 641 provides excellent
control of secondary HPT and diminishes paricalcitol-
mediated vascular calcification. In fact, the combined use
of paricalcitol and calcimimetics may allow the reduction
of the dose of paricalcitol needed to achieve an effective
control of severe HPT and thus prevent the development of
calcifications.
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To the Editor: We were interested to read the study of
increased mortality in chronic kidney disease patients with
secondary hyperparathyroidism by Kovesdy et al.1 They
reported that secondary hyperparathyroidism is indepen-
dently associated with higher mortality rates in chronic
kidney disease patients not yet on dialysis. We have some
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